Skip to Main Content

Paper Details

An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.
Cancer Discov
29
2022
AML, BCL2, CRISPR, CRISPR-competent AML, Cas9, MARCH5, PDX, SLC5A3, acute myeloid leukemia, cancer, established cell lines, hematologic malignancy, myo-inositol, patient, venetoclax
Author NameAffiliation
Guillaume KugenerThe Broad Institute of MIT and Harvard
Biniam AdaneDana-Farber Cancer Institute and Boston Children's Hospital
Biniam AdaneThe Broad Institute of MIT and Harvard
Joseph D ManciasDana-Farber Cancer Institute
Federica PiccioniThe Broad Institute of MIT and Harvard
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital
Kimberly StegmaierThe Broad Institute of MIT and Harvard
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital
Kimberly StegmaierThe Broad Institute of MIT and Harvard
  • 1 - 9

Datasets

Release 1.2